Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy

BACKGROUND: EGFR mutation subtype is a recognised factor impacting outcomes of patients receiving oral tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC). Evidence for the effect of this factor on outcomes in patients receiving pemetrexed is limited. METHODS: We completed a stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Noronha, Vanita, Patil, Vijay, Joshi, Amit, Chougule, Anuradha, Bhattacharjee, Atanu, Kumar, Rajiv, More, Sucheta, Goud, Supriya, Karpe, Ashay, Ramaswamy, Anant, Pande, Nikhil, Chandrasekharan, Arun, Goel, Alok, Talreja, Vikas, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendu, Prabhash, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5659826/
https://www.ncbi.nlm.nih.gov/pubmed/29104613
http://dx.doi.org/10.3332/ecancer.2017.776

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5659826/
https://www.ncbi.nlm.nih.gov/pubmed/29104613
http://dx.doi.org/10.3332/ecancer.2017.776

Ejemplares similares